uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cardiology-Arrhythmia. (Cardiology)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cardiology-Arrhythmia. (Cardiology)
2012 (English)In: Expert Opinion on Drug Safety, ISSN 1474-0338, Vol. 11, no 4, 671-679 p.Article in journal (Refereed) Published
Abstract [en]


Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia that due to its frequent hospitalizations and increased complication rates imposes a significant health economic burden. Many patients with recurrent AF are admitted to the hospital for cardioversion to restore sinus rhythm. Given this knowledge, it is clearly important to identify a feasible and effective approach for cardioversion of these patients. Cardioversion always requires careful assessment of potential complications, which apart from thromboembolic risks, include proarrhythmias and those related to the deep sedation required for electrical cardioversion. Even though electrical cardioversion is proven to be safe and effective, the need for anesthesia makes alternative strategies more attractive.

Areas covered:

The research discussed is the alternative strategies for cardioversion, including electrical cardioversion and the new relatively atrial-selective antiarrhythmic drug, vernakalant. The literature search methodology undertaken included search in PubMed (cardioversion, vernakalant, conversion as key words).

Expert opinion:

Vernakalant is shown to have good conversion rates, an apparently safe antiarrhythmic profile and is well tolerated in patients with a history of ischemic heart disease. In most cases of recent-onset AF, pharmacological cardioversion can provide a probably more cost-effective and safer alternative to electrical cardioversion, which can then be used as a second option for those who failed the first attempt of cardioversion.

Place, publisher, year, edition, pages
2012. Vol. 11, no 4, 671-679 p.
Keyword [en]
antiarrhythmic; atrial fibrillation; Brinavess; cardioversion; drug; vernakalant
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-175955DOI: 10.1517/14740338.2012.679262ISI: 000305701300014PubMedID: 22632377OAI: oai:DiVA.org:uu-175955DiVA: diva2:533697
Available from: 2012-06-14 Created: 2012-06-14 Last updated: 2012-07-20Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Blomström-Lundqvist, CarinaBlomström, Per
By organisation
In the same journal
Expert Opinion on Drug Safety
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 114 hits
ReferencesLink to record
Permanent link

Direct link